Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Alex Brandon / AP
Tad Lipsky, the acting director of the Federal Trade Commission's Bureau of Competition, has retired five months after being named to his position, the agency said Wednesday. Alan Devlin, the deputy director within the same bureau, also left to work at a private law firm.
Why it matters: The Bureau of Competition oversees mergers and acquisitions and is the FTC's antitrust muscle. The turnover won't help clear the FTC's full plate. However, Lipsky told Axios he had planned to retire from private practice in May but was asked to help with the agency's transition. "An honor to have served but glad to head out now as planned," he said.
Who's next: Markus Meier is the new acting director. Meier led the health care division within the Bureau of Competition and has spearheaded efforts against "pay-for-delay" settlements, in which brand-name drug companies pay generic drug companies to keep their lower-cost medicines off the market.